Additionally, it was observed that in tumour-naïve mice, a single dose of IL-1β dual selective antagonist reduces osteoclast and osteoblast activity and IL-1β expression, also following continuous administration of IL-1β dual selective antagonist for more than 21 days [45]. The gene discussed is IL1B; the disease is neoplasm.